182 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Mainstream Capital Management LLC

Mainstream Capital Management LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 182 shares of the medical research company’s stock, valued at approximately $47,000.

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Alley Investment Management Company LLC boosted its holdings in Amgen by 4.8% in the 4th quarter. Alley Investment Management Company LLC now owns 24,616 shares of the medical research company’s stock valued at $6,416,000 after purchasing an additional 1,138 shares during the period. SWS Partners boosted its holdings in Amgen by 7.9% during the fourth quarter. SWS Partners now owns 885 shares of the medical research company’s stock valued at $231,000 after purchasing an additional 65 shares in the last quarter. Torray Investment Partners LLC grew its position in Amgen by 394.5% in the fourth quarter. Torray Investment Partners LLC now owns 60,127 shares of the medical research company’s stock valued at $15,672,000 after acquiring an additional 47,969 shares during the period. Commerzbank Aktiengesellschaft FI grew its holdings in shares of Amgen by 372.2% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 277,772 shares of the medical research company’s stock worth $72,398,000 after purchasing an additional 218,948 shares during the last quarter. Finally, Synergy Investment Management LLC bought a new stake in Amgen during the fourth quarter worth about $34,000. Institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last 90 days. Company insiders own 0.69% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $310.78 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a market capitalization of $166.95 billion, a P/E ratio of 41.16, a P/E/G ratio of 2.63 and a beta of 0.56. The stock has a 50 day moving average of $281.80 and a 200-day moving average of $299.73. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 126.09%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Bank of America raised their target price on Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research note on Thursday, February 6th. UBS Group restated a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Leerink Partners decreased their price objective on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Citigroup reissued a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $314.09.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.